


A MRD+ patients

	OS (95% CI)	
Overall <i>n</i> = 109	64.7 (52.8–74.2)	
Philadelphia chromosome status		
Ph- (<i>n</i> = 83)	62.4 (49.3–73.1)	
Ph+ (<i>n</i> = 26)	71.7 (38.6–89.0)	
Remission state before blinatumomab initiation in the Ph- subgroup		
CR1 (<i>n</i> = 49)	69.0 (51.6–81.3)	
CR2+ (<i>n</i> = 28)	47.3 (25.0–66.7)	
HSCT before blinatumomab initiation		
No HSCT (<i>n</i> = 92)	64.2 (51.6–74.3)	
HSCT (<i>n</i> = 17)	67.0 (30.5–87.3)	
MRD response within the first two cycles of blinatumomab treatment		
MRD response (incl. complete) (<i>n</i> = 70)	71.5 (56.3–82.2)	
Persistence or relapse (<i>n</i> = 13)	57.1 (25.4–79.6)	



B R/R Ph- patients

	OS (95% CI)	
Overall <i>n</i> = 106	40.0 (28.7–51.0)	
HSCT before blinatumomab initiation		
No HSCT (<i>n</i> = 63)	33.6 (18.7–49.2)	
HSCT (<i>n</i> = 43)	48.6 (31.5–63.7)	
Percentage of bone blasts at blinatumomab initiation		
< 50% (<i>n</i> = 62)	45.5 (30.5–59.2)	
≥ 50% (<i>n</i> = 44)	33.0 (17.6–49.4)	
CR/CRh/CRi within the first two cycles of blinatumomab treatment		
CR/CRh/CRi (<i>n</i> = 54)	56.1 (39.9–69.5)	
Refractory or other (<i>n</i> = 49)	22.2 (8.5–39.9)	
MRD response within the first two cycles of blinatumomab treatment		
MRD response (incl. complete) (<i>n</i> = 35)	71.8 (50.1–85.3)	
Persistence or relapse (<i>n</i> = 7)	21.4 (1.2–58.6)	



C R/R Ph+ patients

	OS (95% CI)	
Overall <i>n</i> = 34	44.3 (22.5–64.1)	
HSCT before blinatumomab initiation		
No HSCT (<i>n</i> = 22)	65.0 (40.3–81.5)	
HSCT (<i>n</i> = 12)	NE	
Percentage of bone blasts at blinatumomab initiation		
< 50% (<i>n</i> = 20)	47.4 (19.3–71.2)	
≥ 50% (<i>n</i> = 14)	44.9 (17.7–69.0)	
CR/CRh/CRi within the first two cycles of blinatumomab treatment		
CR/CRh/CRi (<i>n</i> = 14)	56.6 (22.0–80.7)	
Refractory or other (<i>n</i> = 17)	46.4 (19.3–69.9)	
MRD response within the first two cycles of blinatumomab treatment		
MRD response (incl. complete) (<i>n</i> = 8)	NE	
Persistence or relapse (<i>n</i> = 4)	75.0 (12.8–96.1)	

